
About Panome Bio
Panome Bio is a Healthcare company based in St. Louis (United States) founded in 2022. Clinical data analytics services are provided for healthcare applications. Panome Bio has raised $6 million across 1 funding round from investors including Telegraph Hill Partners and BioGenerator Ventures. Panome Bio offers products and services including Next-Generation Metabolomics, Panome Proteomics, Integrated Multi-omics, Targeted Metabolomics, and Global Phosphoproteomics. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Functional Services. Its competitors include Knipper, CDISC and Perceive Now; 1 of its 3 listed competitors has raised funding.
Company details
Panome Bio was established in 2022 in St. Louis, United States, within the healthcare technology sector. Clinical data analytics services are delivered to support research and decision-making processes. Operations center on processing and interpreting clinical datasets for various applications. The company maintains its presence through the domain panomebio.com, serving clients in the United States and potentially beyond. Focus remains on factual data handling without additional sectors noted.
- Headquarters St. Louis, United States
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website panomebio.com
- Social LinkedIn
- Total Equity Funding$6M (USD)
in 1 rounds
- Latest Funding Round$6M (USD), Series A
Feb 2023
- InvestorsTelegraph Hill Partners
& 1 more
Products & Services of Panome Bio
Panome Bio offers a comprehensive portfolio of products and services, including Next-Generation Metabolomics, Panome Proteomics, Integrated Multi-omics, Targeted Metabolomics, and Global Phosphoproteomics.
Provides untargeted metabolomics for biomarker discovery and research.
Enables comprehensive proteome profiling for scientific experiments.
Integrates metabolomics and proteomics data for mechanistic insights.
Offers precise quantitative analysis of specific metabolites.
Maps phosphorylation events in unbiased proteome coverage.
Funding Insights of Panome Bio
Panome Bio has successfully raised a total of $6M through 1 strategic funding round. The most recent funding activity was a Series A round of $6 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6M
- Total Rounds 1
- Last Round Series A β $6M
- First Round $6M
(Feb 2023)
- Investors Count 2
All 1 funding rounds of Panome Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $6M | Series A | β | Telegraph Hill Partners |
2 investors in total: 2 institutional.
Investors in Panome Bio
Panome Bio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Telegraph Hill Partners and BioGenerator Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science, medical device and healthcare companies | thpartners.net | San Francisco, United States | ||
Venture capital and acceleration are provided to life science startups. | biogeneratorventures.com | St. Louis, United States |
Investor details for Panome Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Panome Bio
7 people are tracked at Panome Bio (4 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Edward Weinstein | Co-Founder and CEO | Leadership |
Tom Cohen | Co-founder, President, And COO | Leadership |
Christopher Eden, Ph.D | Senior Director Of Business Development | Leadership |
Alexandra Harrison | Director Of Marketing | Leadership |
Jessica Richardson | Business Development Manager | Team |
Kelly Barrett | Business Development Manager | Team |
Arnold Sewall | Business Development Manager - East Coast | Team |
Complete people profiles for Panome Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Panome Bio
2 dated milestones of Panome Bio across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Panome Bio is founded.
- Funding First funding round of $6.0M.
Competitors of Panome Bio
Panome Bio has 3 listed competitors in our database, 1 of them funded. They include Knipper, CDISC and Perceive Now.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| knipper.com | 1986 | Lakewood Township, United States | Provider of diversified outsourcing services for pharmaceutical, biotech, and medical device companies | |||
| cdisc.org | 1999 | Austin, United States | Provider of data management services | |||
| perceivenow.ai | 2020 | Cincinnati, United States | $150,000 | Data management services are provided by Perceive Now. |
Detailed competitors of Panome Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Panome Bio
The website of Panome Bio (panomebio.com) receives about 4.2K visits a month.
- Monthly visits4.2K
▼ 22.2% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Panome Bio (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Panome Bio
Complete news archive for Panome Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Panome Bio
Panome Bio was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Panome Bio is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.
Panome Bio is a funded company, having raised a total of $6M across 1 funding round to date. The company's 1st funding round was a Series A of $6M, raised on Feb 2023.
Panome Bio was established in 2022 in St. Louis, United States, within the healthcare technology sector. Clinical data analytics services are delivered to support research and decision-making processes. Operations center on processing and interpreting clinical datasets for various applications. The company maintains its presence through the domain panomebio.com, serving clients in the United States and potentially beyond. Focus remains on factual data handling without additional sectors noted.
Panome Bio's top competitors include Knipper, CDISC and Perceive Now.
Panome Bio offers Next-Generation Metabolomics, Panome Proteomics, Integrated Multi-omics, Targeted Metabolomics, and Global Phosphoproteomics.
Panome Bio has 2 investors. Key investors include Telegraph Hill Partners, and BioGenerator Ventures.
